New Lung Cancer Immunotherapy Set to Start Clinical Trials
the Cancer Therapy Advisor take:
Boehringer Ingelheim and CureVac have announced the start of their collaboration to begin clinical trial for a vaccine in early clinical development for the treatment of patients with lung cancer.
The novel mRNA vaccine, currently known as CV9202 was developed by CureVac, and Boehringer Ingelheim will initiate clinical trials of CV9202 for the treatment of patients with advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) in combination with the tyrosine kinase inhibitor, afatinib, and in patients with unresectable stage 3 NSCLC in combination with chemotherapy and radiation.
CureVac's CV9202 is a combination of mRNA molecules that code for six antigens overexpressed in NSCLC. These mRNA molecules function by inducing an immune response in the body to fight the tumor. CV9202 will be one of the first novel investigational therapeutic mRNA vaccines to undergo clinical trials. CureVac has developed other mRNA vaccines that are currently being tested in patients with castration-resistant prostate cancer and NSCLC.
Afatinib is once-daily tyrosine kinase inhibitor used for the treatment of EGFR mutation-positive metastatic NSCLC.
Early clinical development for vaccine in the treatment of patients with lung cancer.
Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, today jointly announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer.
Boehringer Ingelheim will start clinical investigation of CV9202 in at least two different lung cancer settings, in combination with afatinib in patients with advanced or metastatic epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) and in combination with chemo-radiation therapy in patients with unresectable stage III NSCLC. CureVac receives EUR 35 million (approximately $45 million). Further, CureVac can achieve milestone payments of up to EUR 430 million (approximately $556 million) and royalties on sales.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed